Advance the development of SCY-247, a novel antifungal currently in Phase 1 clinical trials, for the treatment of invasive candidiasis and prophylaxis of invasive fungal disease as oral and IC formula

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

BARDA - ASPR / DAAPPO / BARDA DCMA

Contract Value

Not provided

Codes & Classification
Solicitation Number

BAA-23-100-SOL-00004

NAICS

-

Classification Code

-

Additional Details
Set Aside

None

Place of Performance

Jersey City, New Jersey, UNITED STATES

SourceSAM
The Department of Health and Human Services, through the Office of the Assistant Secretary for Preparedness and Response (ASPR) and its Biomedical Advanced Research and Development Authority (BARDA), has issued an award notice for the continued development of SCY-247, a novel antifungal agent. This procurement activity is focused on advancing SCY-247, which is currently in Phase 1 clinical trials, for the treatment of invasive candidiasis and for the prophylaxis of invasive fungal diseases. The formulation development encompasses both oral and intravenous (IC) delivery methods, aiming to address critical needs in the management and prevention of serious fungal infections. The scope of this initiative includes supporting the further clinical and pharmaceutical development of SCY-247, with the intended outcome of expanding therapeutic options for patients at risk of or suffering from invasive fungal diseases. The project is expected to contribute to the preparedness and response capabilities of the United States by enhancing the arsenal of antifungal agents available for public health emergencies and routine clinical use. Key requirements and objectives of this procurement include the demonstration of safety and efficacy of SCY-247 in relevant clinical settings, the development and validation of both oral and intravenous formulations, and the generation of data necessary to support regulatory submissions. The expected deliverables encompass clinical trial results, formulation data, and documentation suitable for advancing SCY-247 through subsequent phases of development and eventual approval. The place of performance for this contract is Jersey City, New Jersey, United States. The contracting entity responsible for this award is BARDA, operating under the ASPR/DAAPPO/BARDA DCMA office. The primary and secondary points of contact for this procurement are Audrey Glover ([email protected]) and Veronica Stroud ([email protected]), respectively. This procurement is classified as an award notice under the identifier BAA-23-100-SOL-00004 and is currently active. Interested parties can find further details and monitor updates via the official SAM.gov opportunity page at https://sam.gov/opp/5d2b1c5f6d094d72ad9916f20fc33ed3/view. Contractors evaluating this opportunity should note that the focus is on advanced clinical and pharmaceutical development of a novel antifungal agent, with an emphasis on both treatment and prophylactic applications. The project aligns with federal priorities in public health preparedness and requires expertise in clinical trials, regulatory strategy, and pharmaceutical formulation. No specific set-aside requirements or special considerations are indicated in the notice. The core elements of this procurement—clinical advancement of SCY-247, formulation development, and regulatory support—are expected to remain constant throughout the contract lifecycle.